1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Proto Oncogene Market & Clinical Pipeline Insight 2024

Global Proto Oncogene Market & Clinical Pipeline Insight 2024

  • February 2018
  • 440 pages
  • ID: 5312878

Summary

Table of Contents

“Global Proto Oncogene Market & Clinical Pipeline Insight 2024” report gives comprehensive insight on ongoing clinical and non-clinical parameters involved in the development of global proto oncogene market in recent years.

Currently there are 19 proto oncogene inhibitors drugs commercially available in the market and 166 are in clinical pipeline in various developmental phases.

“Global Proto Oncogene Market & Clinical Pipeline Insight 2024” report highlights:
• Oncogenes as Therapeutic Targets for Treatment
• Market Analysis of Proto Oncogene Therapeutic Drugs
• Dosage & Price Analysis of Drugs
• Patent & Approval Year Insight
• Proto Oncogene Inhibitors Clinical Pipeline by Company, Indication & Phase
• Marketed Proto Oncogene Inhibitors Clinical Insight by Company & Indication

Cancer has been designated as a complex genetic and cellular disease as it affects growth of cells due to sudden alterations in the genes. However, most of the conventional anti-cancer therapies developed for treating cancer were directed towards killing the tumor cells and were ineffective in inhibiting the cancer-causing transformations that occur in genes of normal cells. 

Nevertheless several modern cancer therapies have been recently developed including targeted drugs and immunotherapeutics. Although these regimens interrupt the expression of cancer genes but either by affecting the gene indirectly or with lesser efficacy which further leads to ineffective treatment of cancer. 

Proto-oncogene Inhibitors are recently developed class of anti-cancer therapeutics possessing a unique mode of action as they directly inhibit the activation of cancer causing genes. Proto-oncogenes are inactivated form of cancerous genes which function normally until they’re activated by several factors or cellular mechanisms. When such factors activate proto-oncogene, then it gets transformed to form an oncogene which induces cancer development. Proto-oncogene Inhibitors are involved in direct inhibition of this transformation from inactive proto-oncogene to active oncogene and restricting cancer growth. 

Global Cancer Therapy Market has been flourished with a wide range of proto-oncogene inhibitors in the past decade and has acquired a larger portion of the market. 

Furthermore, presence of a wide variety of proto-oncogenes in a human body has provided several targets for developing unique proto-oncogene inhibitors. These facts clearly indicate that proto-oncogene inhibitors is a major class of anti-cancer therapeutics comprising a wide variety of inhibitors based on different proteins and mechanisms which are affected by particular oncogenes.

Proto-oncogene Inhibitors represent a well-established global market as it possess close to 20 commercialized products amongst which more than 5 are in the list of top selling anti-cancer drugs. For instance, Imatinib is one of the proto-oncogene inhibitors which have collected more than US$ 10 Billion in past four to five years. Additionally, another proto-oncogene inhibitor namely Sutent has generated US$ 2 Billion in past three years. 

Moreover more than 20 drugs are in the later phases of clinical pipeline and are expected to be approved in the coming four to five years. Furthermore, Biosimilars of highly popular proto-oncogene inhibitors have already been commercialized and have gained an excellent response in the market. Patent expiration of other popular proto-oncogene inhibitors will provide opportunities for the development and commercialization of more biosimilars. 

Nonetheless, as proto-oncogene inhibitors are a larger class of anti-cancer therapeutics, development and advancement in genomic studies have successfully led to identification of more targets to form proto-oncogene inhibitors. 

Due to this reason, proto-oncogene inhibitors market is expected to expand with the entrance of more sub-classes of drugs under this class. This indicates that although proto-oncogene inhibitor market is well-established yet highly opportunistic for the scientific community as well as the pharmaceutical market. 

Initially approved products in the proto-oncogene inhibitor market such as Imatinib has stayed in the market since 2001 and has continuously generated high revenues; even in the presence of highly competitive market with successive approvals of new proto-oncogene Inhibitors. Such examples are appropriate examples suggest that Global proto-oncogene market will continue to grow exponentially even in a highly competitive market space. 

Proto-oncogene inhibitors are actively being supported by large scale as well as small scale pharmaceutical companies from different regions of the world. Key market players are Dexa Medica, Eisai Pharmaceuticals, Exelixis, Pfizer, Novartis, AstraZeneca and many more. 

Additionally, investments and funding from private as well as public sector is further an encouraging factor for the research laboratories and science institutes to develop unique proto-oncogene inhibitors indicating that this market is expected to grow at an unusually high growth rate in the coming future.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2018

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2018SummaryGranulocyte Macrophage Colony Stimulating ...

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018

  • $ 3500
  • November 2018

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018SummaryAccording to the recently published report ’SerineThreonine ...

Animal Vaccines Sector: Worldwide Forecast until 2022

Animal Vaccines Sector: Worldwide Forecast until 2022

  • $ 2500
  • October 2018

About Animal VaccinesAnimal vaccines are biological preparations used to stimulate the immune system of animals to develop adaptive immunity to a pathogen. All animal vaccines undergo regulatory approval ...


ref:plp2018

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on